Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:204-210
Published online before print October 26, 2006, doi: 10.1161/01.ATV.0000251007.07648.81
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/1/204    most recent
01.ATV.0000251007.07648.81v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Wanrooij, E. J.A
Right arrow Articles by Kuiper, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Wanrooij, E. J.A
Right arrow Articles by Kuiper, J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Pathophysiology
Right arrow Gene expression
Right arrow Growth factors/cytokines
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:204.)
© 2007 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) Pathway Attenuates Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice

Eva J.A van Wanrooij; Gijs H.M van Puijvelde; Paula de Vos; Hideo Yagita; Theo J.C. van Berkel; Johan Kuiper

From the Division of Biopharmaceutics (E.J.A.v.W., G.H.M.v.P., P.d.V., T.J.C.v.B., J.K.), Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden, The Netherlands; and the Department of Immunology (H.Y.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.

Correspondence to Eva J.A. van Wanrooij, Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands. E-mail e.van.wanrooij{at}chem.leidenuniv.nl

Objective— Atherosclerosis is a chronic (auto-)inflammatory disease and T cell activation is an important factor in this process. Tnfrsf4 (OX40) and Tnfsf4 (OX40 ligand) are members of the tumor necrosis factor (TNF) and TNF receptor family and OX40/OX40L mediated signaling is important in co-activation of T cells and facilitates B-T cell interaction. In this study we assessed the role of the OX40/OX40L pathway in atherosclerosis and the effect of interruption of the OX40/OX40L pathway on lesion development.

Methods and Results— We treated low-density lipoprotein receptor-deficient (LDLr–/–) mice with an anti-OX40L antibody which lead to a 53% decrease in atherosclerotic lesion formation. Treatment resulted in inhibition of Th2 mediated isotype switching by decreasing interleukin (IL)-4 secretion and subsequent low IgG1 serum levels against oxLDL, whereas protective anti-oxLDL specific IgM titers were increased in treated mice compared with control.

Conclusions— We conclude that blocking the OX-40/OX40L interaction reduced atherogenesis by inhibition of IL-4 mediated Th2 induced isotype switching and subsequent increased levels of anti-oxLDL IgM.

Tnfrsf4 (OX40) and Tnfsf4 (OX40 ligand) are members of the TNF and TNF receptor family and the OX40/OX40L pathway is an important co-activator of T cells. Anti-OX40 ligand antibody administration reduced atherogenesis by inhibiting IL-4 induced IgG1 isotype switching, and increased anti-oxLDL specific IgM serum levels.


Key Words: atherosclerosis • OX40 • OX40L • isotypeswitch • IgM




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
P. Libby, P. M. Ridker, G. K. Hansson, and for the Leducq Transatlantic Network on Atherothro
Inflammation in Atherosclerosis: From Pathophysiology to Practice
J. Am. Coll. Cardiol., December 1, 2009; 54(23): 2129 - 2138.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Gotsman, A. H. Sharpe, and A. H. Lichtman
T-Cell Costimulation and Coinhibition in Atherosclerosis
Circ. Res., November 21, 2008; 103(11): 1220 - 1231.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Malarstig, P. Eriksson, L. Rose, K. A. Diehl, A. Hamsten, P. M Ridker, and R. Y.L. Zee
Genetic Variants of Tumor Necrosis Factor Superfamily, Member 4 (TNFSF4), and Risk of Incident Atherothrombosis and Venous Thromboembolism
Clin. Chem., May 1, 2008; 54(5): 833 - 840.
[Abstract] [Full Text] [PDF]